Levetiracetam Treatment of Panic Disorder and Lactate-Induced Panic Attacks - Full Text View

Purpose

The main purpose of this research study is to determine whether the drug Levetiracetam (Keppra™) is effective in the prevention of panic attacks. The drug Levetiracetam (Keppra™) has been approved for the treatment of seizures by the U.S. Federal Food and Drug Administration (FDA) and is available by prescription. Levetiracetam has not been approved by the FDA for the treatment of panic disorder.

Condition	Intervention	Phase
Panic Disorder	Drug: levetiracetam	Phase III

MedlinePlus related topics:

Panic Disorder

Drug Information available for:

Levetiracetam Lactic acid Ammonium lactate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment

Official Title:	Levetiracetam Treatment of Panic Disorder and Lactate-Induced Panic Attacks

Further study details as provided by University of Cincinnati:

Show Detailed Description

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both

Criteria

Inclusion Criteria:

Outpatient subjects age 18 years or older.
Subjects must meet DSM-IV-TR criteria for panic disorder with or without agoraphobia.
Subjects must experience a minimum of one panic attack per week over the month preceding the study.
Subjects must be fluent in English.
Subjects must be able to provide and understand written informed consent.

Exclusion Criteria:

Subjects unable to provide and understand written informed consent.
Subjects previously treated with levetiracetam.
Subjects who meet DVM-IV-TR criteria for current diagnosis of mood, psychotic or substance use disorder.
Subjects who have acute or unstable medical illness.
Subjects with a history of seizures or structural brain damage from trauma.
Subjects currently receiving successful treatment for panic disorder (i.e., subjects will not have medications discontinued to participate in the study if they are effective in the treatment of their panic attacks).
Subjects susceptible to lactate infusions.
Female subjects who are pregnant or lactating.
Female subjects who, if fertile, are not using medically acceptable and reliable method of contraception.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00279617

Locations


United States, Ohio
	University of Cincinnati Medical Center
	Cincinnati, Ohio, United States, 45267-0559

Sponsors and Collaborators

University of Cincinnati

UCB

Investigators


Principal Investigator:	Paul Keck, MD	University of Cincinnati

More Information

Study ID Numbers:	2-Miefert
First Received:	January 18, 2006
Last Updated:	October 25, 2007
ClinicalTrials.gov Identifier:	NCT00279617
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Panic Disorder

Anxiety Disorders

Mental Disorders

Etiracetam

Additional relevant MeSH terms:

Nootropic Agents

Pathologic Processes

Disease

Therapeutic Uses

Central Nervous System Agents

Pharmacologic Actions

Anticonvulsants

ClinicalTrials.gov processed this record on October 24, 2008

Sponsors and Collaborators:	University of Cincinnati UCB
Information provided by:	University of Cincinnati
ClinicalTrials.gov Identifier:	NCT00279617